Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK08 Monotherapy and Combination in Advanced Solid Tumors
NCT05620134Phase 2Active, not recruiting
- Sponsor
- Salubris Biotherapeutics
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of JK08 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), sponsored by Salubris Biotherapeutics. Started Oct 2022; status: active, not recruiting.
02
Drugs
JK08
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05620134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620134.